ACHC Maintained at Buy by TD Cowen, Price Target $30 – Apr 2026

TD Cowen maintained its Buy rating on Acadia Healthcare (ACHC) while raising the price target to $30 from $24. The analyst firm’s confidence in the behavioral healthcare operator reflects optimism about operational execution and market positioning. ACHC analyst rating remains supported by 13 Buy votes against just 5 Holds and 1 Sell across the Street. The stock trades at $27.58, down 2.02% on the day, with a market cap of $2.54 billion. Earnings are scheduled for April 29, 2026.

TD Cowen Maintains Buy Rating with Raised Price Target

ACHC analyst rating stays positive

TD Cowen’s maintained Buy rating signals continued confidence in Acadia Healthcare’s strategic direction. The firm raised its price target to $30 from $24, implying 8.8% upside from current levels. This 25% increase in the price target reflects the analyst’s belief in the company’s ability to execute on growth initiatives and improve operational metrics. The rating maintenance suggests no material change in the investment thesis, despite near-term market volatility.

Analyst consensus remains constructive

Across Wall Street, the ACHC analyst rating consensus leans bullish. Thirteen analysts rate the stock as Buy, while five maintain Hold positions and one rates it Sell. This 13-to-5 Buy-to-Hold ratio demonstrates broad support for the behavioral healthcare operator. The consensus rating of 3.0 (on a scale where 1 is Strong Buy and 5 is Strong Sell) reflects moderate bullish sentiment. Investors should note that analyst ratings can change based on quarterly results and operational developments.

Stock Performance and Valuation Metrics

Current trading levels and momentum

ACHC trades at $27.58, down $0.57 or 2.02% on the session. The stock has recovered significantly year-to-date, gaining 94.36%, though it remains below its 52-week high of $28.49. Volume of 2.6 million shares traded below the 3.45 million average, suggesting moderate investor interest. The price sits between the 50-day moving average of $23.66 and the 200-day average of $20.27, indicating an uptrend. Technical indicators show RSI at 62.84 and ADX at 36.20, signaling a strong trend with moderate momentum.

Valuation relative to peers

ACHC trades at a price-to-sales ratio of 0.77x, below the healthcare sector median. The price-to-book ratio of 1.28x reflects modest premium valuation. However, the negative earnings per share of -$12.16 and negative net profit margin of -33.3% highlight profitability challenges. The company’s enterprise value of $5.06 billion against trailing revenues of $3.37 billion yields an EV-to-Sales multiple of 1.53x. These metrics suggest the market is pricing in near-term losses while betting on operational turnaround.

Meyka AI Grade and Financial Health Assessment

Meyka AI rates ACHC with a B grade

Meyka AI rates ACHC with a grade of B, reflecting a Hold recommendation. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The score of 62.75 out of 100 places the stock in the middle range of quality. Meyka’s grading methodology weighs sector comparison at 16%, industry comparison at 16%, and analyst consensus at 14%. These grades are not guaranteed and we are not financial advisors.

Financial challenges and operational metrics

Acadia Healthcare faces significant profitability headwinds. Net income per share stands at -$12.19, reflecting ongoing losses. Operating cash flow per share of $1.46 remains positive, though free cash flow per share is negative at -$4.86. The debt-to-equity ratio of 1.36x indicates moderate leverage. Interest coverage of 2.33x provides limited cushion for debt service. Revenue growth of 5.04% year-over-year shows modest expansion, but EBIT declined 302% and net income fell 531%, signaling operational stress.

Behavioral Healthcare Market Dynamics and Outlook

Industry tailwinds supporting ACHC

Acadia Healthcare operates 238 behavioral healthcare facilities with approximately 10,600 beds across the United States and Puerto Rico. The behavioral healthcare sector benefits from rising demand for mental health and substance abuse treatment services. Demographic trends, including aging populations and increased mental health awareness, support long-term growth. The company’s diversified facility portfolio across inpatient psychiatric hospitals, specialty treatment centers, and residential facilities provides revenue stability. Management’s focus on operational efficiency and margin expansion aligns with investor expectations.

Earnings announcement and forward catalysts

Earnings are scheduled for April 29, 2026, providing a near-term catalyst for stock movement. Investors will focus on occupancy rates, average daily census, and pricing trends across the facility network. Management guidance on capital allocation, debt reduction, and margin improvement will be critical. The company’s ability to demonstrate profitability improvement and cash flow generation will validate the analyst community’s constructive stance. Any surprises on these metrics could trigger significant rating or price target revisions.

Final Thoughts

TD Cowen’s Buy rating and $30 price target reflect confidence in Acadia Healthcare’s long-term prospects, supported by 13 analyst Buys versus 5 Holds. The stock’s 94% year-to-date gain shows investor optimism about behavioral healthcare demand. However, negative earnings, high leverage, and weak free cash flow present risks. Upcoming April 29 earnings will be critical for validating the bullish case. Investors should carefully monitor occupancy trends, margin improvement, and debt management before investing.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.